BIO-PATH HOLDINGS, INC.
BPTH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BPTH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BPTH
Bio-Path Holdings, Inc. is a clinical-stage biotechnology company developing RNAi antisense nanoparticle drug candidates for cancer, obesity, and autoimmune diseases, currently facing severe financial constraints with minimal cash and an accumulated deficit of $126.0 million.
Key risk: Liquidity crisis
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 3 pipeline candidates for BIO-PATH HOLDINGS, INC..
Bio-Path Holdings, Inc. is a clinical-stage biotechnology company developing RNAi antisense nanoparticle drug candidates for cancer, obesity, and autoimmune diseases, currently facing severe financial constraints with minimal cash and an accumulated deficit of $126.0 million.
- Developing RNAi antisense nanoparticle drug candidates based on proprietary technology for cancer, obesity, metabolic diseases, and autoimmune disorders [sec_mda · as of 2025-08-14].
- Pipeline includes prexigebersen, BP1002, BP1003, and BP1001-A, with a molecular biomarker package to identify patients more likely to respond to prexigebersen [sec_mda · as of 2026-01-13].
- Cash & equivalents of $0.0M as of 2026-03-31; net loss of $0.3M for the three months ended March 31, 2026 [sec].
- Accumulated deficit of $126.0 million as of March 31, 2026; net loss was $1.0 million for the three months ended March 31, 2026 [sec_mda · as of 2026-05-20].
- Expects to continue incurring significant operating losses and requires substantial additional capital to fund development and commercialization [sec_mda · as of 2026-01-13].
What works
- Proprietary RNAi antisense nanoparticle platform technology with potential applications across multiple therapeutic areas including cancer, obesity, and autoimmune disorders [sec_mda · as of 2025-08-14].
- Developing a molecular biomarker package to accompany prexigebersen treatment, aiming to identify patients with a genetic profile more likely to respond and improve probability of success [sec_mda · as of 2026-01-13].
- Intellectual property portfolio supporting four drug candidates in clinical development: prexigebersen, BP1002, BP1003, and BP1001-A [sec_mda · as of 2025-08-14].
What to weigh
- Cash & equivalents of $0.0M as of 2026-03-31, with shareholders' equity of only $0.2M and total debt of $0.5M, indicating severe liquidity constraints [sec].
- Accumulated deficit of $126.0 million as of March 31, 2026, and net loss of $1.0 million for the three months ended March 31, 2026 [sec_mda · as of 2026-05-20].
- Cannot reasonably estimate the nature, timing, or costs to complete development of drug candidates or when material net cash inflows may commence [sec_mda · as of 2026-05-20].
- Expects to continue incurring significant operating losses and may not be able to raise additional capital on favorable terms or at all [sec_mda · as of 2026-01-13].
From the filings
Quoted directly from source documents.
Accumulated deficit is substantial
“As of March 31, 2026, we had an accumulated deficit of $126.0 million.”
SEC MD&A · May 20, 2026
Company is developing RNAi antisense nanoparticle drug candidates
“We are developing RNAi antisense nanoparticle drug candidates based on our own patented technology to treat cancer, obesity and related metabolic diseases, and autoimmune disorders”
SEC MD&A · August 14, 2025
Company cannot estimate development timeline or costs
“we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete development of our drug candidates or the period, if any, in which material net cash inflows from our drug candidates may commence.”
SEC MD&A · May 20, 2026
Risks & what to watch (3)›
Key risks
- Liquidity crisis — Cash & equivalents of $0.0M as of 2026-03-31; may not be able to raise additional capital [sec]
- Development uncertainty
- Continued operating losses — Net loss of $1.0M for Q1 2026; accumulated deficit of $126.0M; expects losses to increase [sec_mda · as of 2026-05-20]
What to watch
- Ability to secure additional financing or partnerships to fund ongoing operations and clinical trials [sec_mda · as of 2026-01-13].
- Progress and results of clinical trials for prexigebersen, BP1002, BP1003, and BP1001-A [sec_mda · as of 2026-01-13].
- Development and validation of the molecular biomarker package for prexigebersen [sec_mda · as of 2026-01-13].
- Any regulatory milestones or updates from the FDA regarding drug candidates [sec_mda · as of 2026-01-13].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run BIO-PATH HOLDINGS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BIO-PATH HOLDINGS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
16.7 months
OCF -$38K · Net income -$270K
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Short Interest
as of May 20, 2026- % of float
- 1.4%
- Days to cover
- 0.4
- Shares short
- 79,346
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BPTH short interestGovernance
Frequently asked questions
What is the AI investment thesis for BIO-PATH HOLDINGS, INC.?
Bio-Path Holdings, Inc. is a clinical-stage biotechnology company developing RNAi antisense nanoparticle drug candidates for cancer, obesity, and autoimmune diseases, currently facing severe financial constraints with minimal cash and an accumulated deficit of $126.0 million.
What is BIO-PATH HOLDINGS, INC.'s lead drug candidate?
BIO-PATH HOLDINGS, INC.'s most advanced tracked candidate is BP1001 (Phase 2) for Acute Myeloid Leukemia (AML).
Who is the CEO of BIO-PATH HOLDINGS, INC.?
Mr. Vikram Paul Grover C.F.A., Esq. is the chief executive officer of BIO-PATH HOLDINGS, INC. (BPTH).
Where is BIO-PATH HOLDINGS, INC. headquartered?
BIO-PATH HOLDINGS, INC. (BPTH) is headquartered in Bellaire, TX, United States.
What therapeutic areas does BIO-PATH HOLDINGS, INC. focus on?
BIO-PATH HOLDINGS, INC. develops therapies across Oncology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.